Compare NRDS & CRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NRDS | CRON |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | EDP Services | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 961.2M |
| IPO Year | 2021 | N/A |
| Metric | NRDS | CRON |
|---|---|---|
| Price | $14.90 | $2.95 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $15.40 | N/A |
| AVG Volume (30 Days) | 902.5K | ★ 3.4M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.93 | 0.09 |
| Revenue | ★ $795,000,000.00 | $132,357,000.00 |
| Revenue This Year | $22.09 | $19.67 |
| Revenue Next Year | $7.18 | $30.56 |
| P/E Ratio | ★ $15.76 | $32.18 |
| Revenue Growth | ★ 24.71 | 19.00 |
| 52 Week Low | $7.55 | $1.60 |
| 52 Week High | $16.24 | $3.43 |
| Indicator | NRDS | CRON |
|---|---|---|
| Relative Strength Index (RSI) | 58.51 | 60.47 |
| Support Level | $13.58 | $2.98 |
| Resistance Level | $15.87 | $3.31 |
| Average True Range (ATR) | 0.59 | 0.22 |
| MACD | -0.16 | 0.05 |
| Stochastic Oscillator | 53.38 | 53.88 |
Nerdwallet Inc is a company that provides consumer-driven advice about personal finance through its platform by connecting individuals and small and mid-sized businesses (SMBs) with providers of financial products. It gets revenue from fees paid by its financial services partners in the form of either revenue per action, revenue per click, revenue per lead and revenue per funded loan arrangements.
Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.